Ipomoea Allergy (Morning Glory Pollen Allergy) - Symptoms, Causes, Treatment & Prevention

Overview

Ipomoea allergy, more commonly referred to as morning‑glory pollen allergy, is an IgE‑mediated hypersensitivity reaction to the airborne pollen produced by plants of the genus Ipomoea (e.g., Ipomoea purpurea, Ipomoea nil). These vines, known as morning glories, are popular ornamental plants worldwide and release copious amounts of pollen during their flowering season (typically late spring to early summer).

While most people experience mild seasonal allergic rhinitis from well‑known pollens such as ragweed or birch, Ipomoea pollen can trigger similar or, in some cases, more severe reactions. The condition is under‑reported because many clinicians do not include it in routine allergy panels, yet surveys from allergy centers in the United States, Japan, and Brazil indicate that 1–3 % of patients with seasonal allergic rhinitis are sensitized to morning‑glory pollen [1][2].

Who is affected? Anyone exposed to high concentrations of morning‑glory pollen can develop an allergy, but certain groups have higher prevalence:

• Individuals with a personal or family history of atopy (asthma, eczema, hay fever).
• People living in areas where morning glories are cultivated widely—urban gardens, parks, and roadside plantings.
• Outdoor workers (landscapers, farmers, gardeners) who have prolonged daily exposure.

Symptoms

The clinical picture mirrors other pollen‑induced allergies, but particular patterns can suggest Ipomoea sensitization:

• Allergic rhinitis – sneezing, itching or burning sensation in the nose, watery rhinorrhea, and nasal congestion.
• Conjunctivitis – red, itchy, watery eyes; often described as “pollen eyes.”
• Upper respiratory symptoms – sore throat, post‑nasal drip, cough.
• Bronchial hyper‑reactivity – wheezing, shortness of breath, especially in patients with asthma.
• Skin manifestations – urticaria (hives) or eczema flare‑ups after direct contact with the plant or its pollen.
• Oral allergy syndrome – itching or swelling of the lips, tongue, or throat after eating raw fruits related to Ipomoea (e.g., certain tuberous roots).
• Late‑phase reaction – symptoms may recur 4–24 hours after initial exposure, indicating persistent inflammation.

Symptoms usually start 5–30 minutes after exposure and can last several hours to days, depending on pollen load and individual sensitivity.

Causes and Risk Factors

Pathophysiology

Morning‑glory pollen contains several allergenic proteins (e.g., Ipomoea‑1, Ipomoea‑2). In sensitized individuals, the immune system mistakenly classifies these proteins as harmful, producing specific IgE antibodies. Upon re‑exposure, the IgE bound to mast cells and basophils triggers the release of histamine, leukotrienes, and other mediators that cause the classic allergy symptoms.

Risk Factors

• Atopic background – pre‑existing eczema, asthma, or allergic rhinitis.
• Geographic location – warm climates where morning glories bloom abundantly (southern U.S., Mediterranean, parts of Asia and South America).
• Occupational exposure – landscaping, horticulture, and agricultural work.
• Genetic predisposition – family members with pollen allergies increase personal risk.
• High indoor pollen load – open windows, lack of air filtration, and indoor potted morning‑glory plants.

Diagnosis

Diagnosing an Ipomoea pollen allergy involves a combination of clinical history, seasonal correlation, and objective testing.

Clinical Evaluation

• Detailed history of symptom timing, location, and possible plant exposure.
• Physical examination focusing on nasal mucosa, conjunctiva, skin, and lung auscultation.

Allergy Testing

1. Skin Prick Test (SPT) – a drop of standardized morning‑glory pollen extract is placed on the forearm; a positive reaction (wheal ≥3 mm) within 15 minutes supports sensitization.
2. Specific IgE Blood Test – ImmunoCAP or similar assays quantify IgE antibodies to Ipomoea allergens. Values >0.35 kU/L are considered positive.
3. Component‑Resolved Diagnostics – newer panels can identify IgE to individual protein components (e.g., Ipomoea‑1), helping differentiate true allergy from cross‑reactivity.

Additional Assessments

• Peak Flow Monitoring – for patients with asthma, documenting lung function changes during pollen season.
• Nasally‑administered allergen challenge – performed in specialized allergy clinics when diagnosis remains uncertain.

Treatment Options

Treatment follows the step‑wise approach used for other seasonal allergies, with adjustments for severity and comorbidities.

Pharmacologic Therapies

• Antihistamines – second‑generation agents (cetirizine, loratadine, fexofenadine) provide rapid relief without sedation.
• Nasal corticosteroids – fluticasone, mometasone, or budesonide spray reduce inflammation; they are first‑line for persistent rhinitis.
• Leukotriene receptor antagonists – montelukast may benefit patients with concomitant asthma or when antihistamines are insufficient.
• Decongestants – oral pseudoephedrine or topical oxymetazoline for short‑term relief of nasal congestion (limited to <5 days to avoid rebound congestion).
• Eye drops – olopatadine or ketotifen for allergic conjunctivitis.
• Bronchodilators – short‑acting β2‑agonists (albuterol) for asthma exacerbations triggered by pollen.

Allergen‑Specific Immunotherapy (AIT)

For patients with moderate‑to‑severe disease unresponsive to medications, subcutaneous (SCIT) or sublingual (SLIT) immunotherapy with standardized morning‑glory pollen extracts can induce long‑term tolerance. Clinical trials show a 30–50 % reduction in symptom scores** after 3‑4 years of therapy* [3].